Scott Ed­mond­son leaves As­traZeneca, starts new chap­ter at Nim­bus; With IPO filed, Taysha pulls to­geth­er an AveX­is-heavy team

Nim­bus Ther­a­peu­tics, which iden­ti­fied 4 new tar­gets – AMP­Kβ2, CTPS1, Cbl-b and WRN – in their drug dis­cov­ery ef­forts,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.